Neutralizing ceramide: a major breakthrough or yet another marginal target for the treatment of acute lung injury?
Mercier
Jean-Christophe
JC
Dinh-Xuan
A Tuan
AT
D018759:Adrenergic Uptake Inhibitors / Q000627:therapeutic use; D000818:Animals; D001952:Bridged-Ring Compounds / Q000627:therapeutic use*; D002518:Ceramides / Q000037:antagonists & inhibitors* / Q000378:metabolism; D004487:Edema / Q000517:prevention & control; D006801:Humans; D007099:Imipramine / Q000627:therapeutic use; D051379:Mice; D009636:Norbornanes; D010726:Phosphodiesterase Inhibitors / Q000627:therapeutic use*; D012128:Respiratory Distress Syndrome / Q000188:drug therapy* / Q000378:metabolism; D013108:Sphingomyelin Phosphodiesterase / Q000037:antagonists & inhibitors; D013859:Thiocarbamates; D013871:Thiones / Q000627:therapeutic use*
D018759:Adrenergic Uptake Inhibitors; D001952:Bridged-Ring Compounds; D002518:Ceramides; D009636:Norbornanes; D010726:Phosphodiesterase Inhibitors; D013859:Thiocarbamates; D013871:Thiones; C046498:tricyclodecane-9-yl-xanthogenate; D013108:Sphingomyelin Phosphodiesterase; D007099:Imipramine